檢索結果 - Steven Coutré

Refine Results
  1. 1
    Role of envelope glycoprotein carbohydrate in human immunodeficiency virus (HIV) infectivity and virus-induced cell fusion.

    Role of envelope glycoprotein carbohydrate in human immunodeficiency virus (HIV) infectivity and virus-induced cell fusion. 由 Jeffrey D. Lifson, Steven Coutré, Erich Huang, E G Engleman

    出版 1986
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management

    The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management 由 Jason Gotlib, Jan Cools, James Malone, Stanley L. Schrier, D. Gary Gilliland, Steven Coutré

    出版 2003
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management

    Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management 由 David Iberri, Bernice Y. Kwong, Laurel A. Stevens, Steven Coutré, Jinah Kim, Jean Sabile, Ranjana H. Advani

    出版 2016
    獲取全文 獲取全文
    Carta
    加到收藏夾
    Saved in:
  4. 4
    Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p

    Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p 由 James I. Barnes, Vasu Divi, Adrian Begaye, Russell Wong, Steven Coutré, Douglas K Owens, Jeremy D. Goldhaber‐Fiebert

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Treatment advances have not improved the early death rate in acute promyelocytic leukemia

    Treatment advances have not improved the early death rate in acute promyelocytic leukemia 由 James Scott McClellan, Holbrook E. Kohrt, Steven Coutré, Jason Gotlib, Ravindra Majeti, Ash A. Alizadeh, Bruno C. Medeiros

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass

    Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass 由 Abe DeAnda, Steven Coutré, Marc R. Moon, Conrad Vial, Linda C. Griffin, Veronica S. Law, Masashi Komeda, Lawrence Leung, D. Craig Miller

    出版 1994
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

    A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia 由 Sucha Nand, Megan Othus, John E. Godwin, Cheryl L. Willman, Thomas H. Norwood, Dianna S. Howard, Steven Coutré, Harry P. Erba, Frederick R. Appelbaum

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

    Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia 由 Robert J. Kreitman, Martin S. Tallman, Tadeusz Robak, Steven Coutré, Wyndham H. Wilson, Maryalice Stetler‐Stevenson, David J. FitzGerald, Robert J. Lechleider, Ira Pastan

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

    PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma 由 Paul G. Richardson, Robert Schlossman, Melissa Alsina, Donna M. Weber, Steven Coutré, Cristina Gasparetto, Sutapa Mukhopadhyay, Michael S. Ondovik, Md Mahmudul Hasan Khan, Carole Paley, Sagar Lonial

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

    A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535) 由 Jeffrey E. Lancet, Anna Moseley, Steven Coutré, Daniel J. DeAngelo, Megan Othus, Martin S. Tallman, Mark R. Litzow, Rami S. Komrokji, Harry P. Erba, Frederick R. Appelbaum

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

    Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 198... 由 Daniel J. DeAngelo, Daohai Yu, Jeffrey L. Johnson, Steven Coutré, Richard M. Stone, Alison Stopeck, Jon P. Gockerman, Beverly S. Mitchell, Frederick R. Appelbaum, Richard A. Larson

    出版 2007
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia

    SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia 由 Anjali S. Advani, Shannon McDonough, Steven Coutré, Brent L. Wood, Jerald P. Radich, Martha P. Mims, Margaret O’Donnell, S. Elkins, Michael W. Becker, Megan Othus, Frederick R. Appelbaum

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

    Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up 由 Robert J. Kreitman, Martin S. Tallman, Tadeusz Robak, Steven Coutré, Wyndham H. Wilson, Maryalice Stetler‐Stevenson, David J. FitzGerald, Linda Santiago, Guozhi Gao, Mark C. Lanasa, Ira Pastan

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro

    Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro 由 Kenro Kusumi, Barbara R. Conway, Sharon C. Cunningham, Amy E. Berson, Christopher H. Evans, Astrid K. N. Iversen, Daniel C. Colvin, Michael V. Gallo, Steven Coutré, Eugene G. Shpaer

    出版 1992
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all‐<i>trans</i> retinoic acid and arsenic trioxide

    Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all‐<i>trans</i> retinoic acid and arsenic trioxide 由 David Sanford, Francesco Lo‐Coco, Miguel Á. Sanz, Eros Di Bona, Steven Coutré, Jessica K. Altman, Meir Wetzler, Steven L. Allen, Farhad Ravandi, Hagop M. Kantarjian, Jorge E. Cortés

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia

    Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia 由 Daniel A. Pollyea, James L. Zehnder, Steven Coutré, Jason Gotlib, Leonel Gallegos, Omar Abdel‐Wahab, Peter L. Greenberg, Bing Zhang, Michaela Liedtke, Caroline Berube, Ross L. Levine, Beverly S. Mitchell, Bruno C. Medeiros

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia

    Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia 由 Anjali S. Advani, Holly Gundacker, Olga Sala‐Torra, Jerald P. Radich, Raymond Lai, Marilyn L. Slovak, Jeffrey E. Lancet, Steven Coutré, Robert K. Stuart, Martha P. Mims, Patrick J. Stiff, Frederick R. Appelbaum

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

    Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma 由 Wei-Gang Tong, Rong Chen, William Plunkett, David S. Siegel, Rajni Sinha, R. Donald Harvey, Ashraf Badros, Leslie Popplewell, Steven Coutré, Judith A. Fox, Kristi Mahadocon, Tianling Chen, Peggy Kegley, Ute Hoch, William G. Wierda

    出版 2010
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

    Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy 由 Steven Coutré, Michael Y. Choi, Richard R. Furman, Herbert Eradat, Leonard T. Heffner, Jeffrey A. Jones, Brenda Chyla, Lang Zhou, Suresh Agarwal, Tina Waskiewicz, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, William G. Wierda, Matthew S. Davids

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

    A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL) 由 Brad S. Kahl, Stephen E. Spurgeon, Richard R. Furman, Ian W. Flinn, Steven Coutré, Jennifer R. Brown, Don M. Benson, John C. Byrd, Sissy Peterman, Yoonjin Cho, Albert S. Yu, Wayne R. Godfrey, Nina D. Wagner‐Johnston

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: